MA32150B1 - Inhibiteurs heterocycliques de la stearoyl-coa desaturase - Google Patents

Inhibiteurs heterocycliques de la stearoyl-coa desaturase

Info

Publication number
MA32150B1
MA32150B1 MA33156A MA33156A MA32150B1 MA 32150 B1 MA32150 B1 MA 32150B1 MA 33156 A MA33156 A MA 33156A MA 33156 A MA33156 A MA 33156A MA 32150 B1 MA32150 B1 MA 32150B1
Authority
MA
Morocco
Prior art keywords
stearoyl
coa desaturase
heterocyclic inhibitors
heterocyclic
derivatives
Prior art date
Application number
MA33156A
Other languages
Arabic (ar)
English (en)
Inventor
Sultan Chowdhury
Natalie Dales
Julia Fonarev
Jianmin Fu
Duanjie Hou
Qi Jia
Vishnumurthy Kodumuru
Natalia Pokrovskaia
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40740143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32150(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of MA32150B1 publication Critical patent/MA32150B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des dérivés hétérocycliques représentés par la formule (i) qui modulent l'activité de la stéaroyl-coa désaturase. L'invention concerne également des procédés d'utilisation des dérivés qui modulent l'activité de la stéaroyl-coa désaturase et des compositions pharmaceutiques comprenant ces dérivés.
MA33156A 2008-02-20 2010-09-09 Inhibiteurs heterocycliques de la stearoyl-coa desaturase MA32150B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3013708P 2008-02-20 2008-02-20
PCT/EP2009/051926 WO2009103739A1 (fr) 2008-02-20 2009-02-18 Inhibiteurs hétérocycliques de la stéaroyl-coa désaturase

Publications (1)

Publication Number Publication Date
MA32150B1 true MA32150B1 (fr) 2011-03-01

Family

ID=40740143

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33156A MA32150B1 (fr) 2008-02-20 2010-09-09 Inhibiteurs heterocycliques de la stearoyl-coa desaturase

Country Status (29)

Country Link
US (2) US8049016B2 (fr)
EP (1) EP2245029B1 (fr)
JP (2) JP5507474B2 (fr)
KR (1) KR101584826B1 (fr)
CN (1) CN102007123B (fr)
AR (1) AR070429A1 (fr)
AU (1) AU2009216769A1 (fr)
BR (1) BRPI0907826A2 (fr)
CA (1) CA2715947C (fr)
CL (1) CL2009000381A1 (fr)
CO (1) CO6290655A2 (fr)
CR (1) CR11629A (fr)
CU (1) CU23890B1 (fr)
EA (1) EA022797B1 (fr)
EC (1) ECSP10010411A (fr)
HK (1) HK1144808A1 (fr)
HN (1) HN2010001647A (fr)
IL (1) IL207578A (fr)
JO (1) JO3014B1 (fr)
MA (1) MA32150B1 (fr)
MX (1) MX2010009158A (fr)
MY (1) MY156317A (fr)
NZ (1) NZ587350A (fr)
PE (1) PE20091473A1 (fr)
SV (1) SV2010003650A (fr)
TW (1) TWI457338B (fr)
UA (1) UA105000C2 (fr)
WO (1) WO2009103739A1 (fr)
ZA (1) ZA201005725B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002348A1 (es) 2006-08-15 2008-08-08 Novartis Ag Xenon Pharmaceutic Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne.
JP2010513403A (ja) * 2006-12-20 2010-04-30 ノバルティス アーゲー Ｓｃｄ阻害剤としての２−置換５員ヘテロ環
BRPI0907826A2 (pt) 2008-02-20 2019-12-10 Novartis Ag inibidores heterocíclicos de estearoil-coa desaturase
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
SG178869A1 (en) * 2009-10-01 2012-04-27 Novartis Ag Pyrazole derivatives which modulate stearoyl-coa desaturase
TW201350481A (zh) * 2012-05-11 2013-12-16 Abbvie Inc Ｎａｍｐｔ抑制劑
KR20150013548A (ko) 2012-05-21 2015-02-05 노파르티스 아게 키나제 억제제로서의 신규 고리-치환된 n-피리디닐 아미드
JP2019529342A (ja) * 2016-09-08 2019-10-17 四川科倫博泰生物医薬股▲フン▼有限公司Ｓｉｃｈｕａｎ Ｋｅｌｕｎ−Ｂｉｏｔｅｃｈ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 新型２−アミドチアゾール誘導体、及びその製造方法と用途
EP3529245A4 (fr) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. Composés et utilisations de ces derniers
IL304017A (en) 2017-01-06 2023-08-01 Yumanity Therapeutics Inc Methods for treating neurological disorders
CA3083000A1 (fr) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Composes et utilisations de ces composes
CN114222732B (zh) * 2019-10-28 2023-04-04 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH590266A5 (fr) * 1972-10-04 1977-07-29 Ciba Geigy Ag
US4058617A (en) 1972-10-04 1977-11-15 Ciba-Geigy Corporation Imidazoles and pharmaceutical composition
IL44282A (en) 1974-02-25 1979-01-31 Ciba Geigy Ag 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
WO1999021555A2 (fr) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Antagonistes des recepteurs de l'adenosine a¿3?
WO2001010865A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
AU2001244618A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
CA2436739A1 (fr) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Agent de combinaison
EP1402900A1 (fr) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Compositions medicinales
WO2005077937A1 (fr) 2004-01-09 2005-08-25 Cadila Healthcare Limited Derives d'acide hydroxamique substitues utilises comme inhibiteurs de tnf
EP1621539A1 (fr) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Dérivées d'urée cyclique substitués par un heterocycle, leur prépration et leur utilisation pharmaceutique comee inhibiteurs de kinases
BRPI0515500A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
AR051092A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
CN101208089A (zh) * 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
BRPI0712902A2 (pt) * 2006-06-05 2018-10-30 Novartis Ag compostos orgânicos
CL2007002348A1 (es) * 2006-08-15 2008-08-08 Novartis Ag Xenon Pharmaceutic Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne.
JP2010501567A (ja) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
BRPI0718509A2 (pt) * 2006-09-22 2015-09-29 Novartis Ag compostos orgânicos heterocíclicos
GB0621452D0 (en) * 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
JP2010513403A (ja) 2006-12-20 2010-04-30 ノバルティス アーゲー Ｓｃｄ阻害剤としての２−置換５員ヘテロ環
KR20100124262A (ko) * 2008-02-13 2010-11-26 에자이 알앤드디 매니지먼트 가부시키가이샤 비시클로아민 유도체
BRPI0907826A2 (pt) 2008-02-20 2019-12-10 Novartis Ag inibidores heterocíclicos de estearoil-coa desaturase
PE20110136A1 (es) 2008-06-27 2011-03-17 Novartis Ag Compuestos organicos

Also Published As

Publication number Publication date
SV2010003650A (es) 2011-07-05
ECSP10010411A (es) 2010-09-30
TWI457338B (zh) 2014-10-21
UA105000C2 (uk) 2014-04-10
WO2009103739A1 (fr) 2009-08-27
CN102007123A (zh) 2011-04-06
AU2009216769A1 (en) 2009-08-27
US8318949B2 (en) 2012-11-27
PE20091473A1 (es) 2009-10-23
TW200942534A (en) 2009-10-16
US20120014906A1 (en) 2012-01-19
CA2715947C (fr) 2016-10-25
CR11629A (es) 2010-11-16
CL2009000381A1 (es) 2010-09-10
US20090264444A1 (en) 2009-10-22
US8049016B2 (en) 2011-11-01
CO6290655A2 (es) 2011-06-20
KR20100117677A (ko) 2010-11-03
JP2014132025A (ja) 2014-07-17
CA2715947A1 (fr) 2009-08-27
EP2245029A1 (fr) 2010-11-03
IL207578A0 (en) 2010-12-30
JP5507474B2 (ja) 2014-05-28
JO3014B1 (ar) 2016-09-05
JP5813162B2 (ja) 2015-11-17
HN2010001647A (es) 2013-11-11
KR101584826B1 (ko) 2016-01-18
NZ587350A (en) 2012-07-27
EP2245029B1 (fr) 2015-04-15
MY156317A (en) 2016-02-15
JP2011512384A (ja) 2011-04-21
CU20100170A7 (es) 2011-10-31
EA201001315A1 (ru) 2011-06-30
BRPI0907826A2 (pt) 2019-12-10
ZA201005725B (en) 2011-04-28
MX2010009158A (es) 2010-09-24
AR070429A1 (es) 2010-04-07
EA022797B1 (ru) 2016-03-31
CN102007123B (zh) 2014-04-30
CU23890B1 (es) 2013-04-19
HK1144808A1 (en) 2011-03-11
IL207578A (en) 2014-11-30

Similar Documents

Publication Publication Date Title
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA30655B1 (fr) Composes organiques.
MX2009003080A (es) Compuestos organicos heterociclicos.
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
EA201100049A1 (ru) Органические соединения
DK2368887T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MA31874B1 (fr) Inhibiteurs de bêta-lactamases
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA29785B1 (fr) Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
EA200970156A1 (ru) Пиридизиноновые производные
WO2007143597A3 (fr) Composés organiques
WO2008074824A3 (fr) Composés
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA33693B1 (fr) Dérivés de pyrazole qui modulent la stéroyl-coa désaturase
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
WO2007081808A3 (fr) Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
EA200801420A1 (ru) Фармацевтическое средство для лечения уретеролитиаза